Aktuelles – MedicalCooling
MedicalCooling · Aktuelles
Aktuelles
Wichtige Entwicklungen bei Evidenz, klinischer Entwicklung, Regulierung, Erstattung, Patenten, Technologie, Finanzierung und Partnerschaften, die die AIRCHILL-Strategie beeinflussen können.
AIRCHILL ist weiterhin eine Medizintechnologie in Entwicklung, ohne CE-Kennzeichnung und ohne FDA-Zulassung. Die Meldungen unterscheiden externe wissenschaftliche Erkenntnisse und Marktentwicklungen von AIRCHILL-spezifischen Aussagen und erläutern deren Bedeutung für das Entwicklungsprogramm.
Die eingeblendeten einzelnen Nachrichtenbeiträge können noch in englischer Sprache vorliegen.
Neueste Meldungen
-
TBI field-biomarker update: dried capillary plasma could simplify future EMS trial sampling
A 4 September 2026 peer-reviewed TBI methods study shows that dried capillary plasma can preserve GFAP, UCH-L1, NfL and Tau signals, creating a potential future EMS sampling option without changing AIRCHILL clinical claims.
-
ESICM Call 2 is open: opportunity for a neutral ICU consensus project
ESICM Call 2 is open from 7 September to 5 October 2026 for guidelines, consensus statements and position papers, creating a time-limited scientific-network opportunity relevant to early neuroprotection and temperature-management methodology.
-
4 September 2026: new trial benchmarks for ventilation, peri-EVT physiology and device-based cooling
New external trial records sharpen AIRCHILL human-factors, peri-EVT ventilation and regulatory-development planning without changing the current efficacy claims.
-
Technology and IP watch: intranasal cooling, BrainCool/ZOLL, corpuls and liquid ventilation
Recent competitor, patent and platform developments sharpen AIRCHILL’s differentiation around early respiratory cooling, integrated ventilation and EMS interoperability.
-
Funding and partnership opportunities: MEDICA, accelerators, G-BA and international programmes
Time-sensitive 2026 opportunities include MEDICA competitions, MedTech accelerators, German innovation funding, EU programmes and clinical-networking routes.
-
Market access 2026: Germany, EU HTA, NHS value-based procurement and US reimbursement windows
Several 2026 policy and reimbursement changes could materially shape AIRCHILL evidence generation, from German emergency-care reform and G-BA funding to EU HTA consultation and NHS value-based procurement.
-
FDA temperature-management recalls: design lessons for AIRCHILL risk management
FDA Class II recalls affecting Blanketrol II and CoolBlue highlight failure-mode, alarm and fail-safe requirements for future temperature-management systems.
-
Heatstroke 2026: post-stabilisation hypothermia at 35 °C shows no benefit
A 2026 pilot randomized trial found no outcome benefit from maintaining heatstroke patients at 35 °C after initial cooling, while arrhythmias, gastrointestinal injury and shivering treatment increased.
-
ICECAP 2026: cooling duration after cardiac arrest does not improve neurological outcome
ICECAP separates cooling duration from cooling timing: longer hypothermia at 33 °C did not improve neurological outcome, strengthening the need to study timing, route and thermal dose as distinct variables.